Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.48 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
| ▸ | LPL | P06858 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.32 |
| ▸ | KDR | P35968 | 3/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
| ▸ | F11 | P03951 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20746364 | 1.00 | AAK1 (0.48) | AAK1ALPLLPLLIPGDGAT1 | |
| SCHEMBL22026484 | 1.00 | AAK1 (0.48) | AAK1ALPLLPLLIPGDGAT1 | |
| SCHEMBL22067617 | 0.90 | AAK1 (0.43) | AAK1 | |
| SCHEMBL22067623 | 0.90 | AAK1 (0.43) | AAK1 | |
| SCHEMBL23571598 | 0.90 | AAK1 (0.43) | AAK1 | |
| SCHEMBL20763332 | 0.87 | AAK1 (0.48) | AAK1ALPLLPLLIPGDGAT1 | |
| SCHEMBL16175196 | 0.87 | AAK1 (0.46) | AAK1ALPLLPLLIPGDGAT1 | |
| SCHEMBL1690230 | 0.86 | AAK1 (0.47) | AAK1ALPLLPLLIPGDGAT1 | |
| SCHEMBL364697 | 0.86 | AAK1 (0.47) | AAK1ALPLLPLLIPGDGAT1 | |
| SCHEMBL10198423 | 0.86 | AAK1 (0.47) | AAK1ALPLLPLLIPGDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116885-A1 | ION CHANNEL MODULATORS | PRAXIS PREC MEDICINES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250376475-A1 | ION CHANNEL MODULATORS | PRAXIS PREC MEDICINES INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-12344615-B2 | Substituted pyridines as ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250163068-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250145629-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2025-05-08 | — | — | US | disclosed |
| US-20250129066-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2025-04-24 | — | — | US | disclosed |
| EP-4487916-A2 | ION CHANNEL MODULATORS | Praxis Precision Medicines, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| US-12145939-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| EP-4397308-A2 | COMPOUNDS AND THEIR METHODS OFUSE | Praxis Precision Medicines, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| US-12030881-B2 | Ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20210087197-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2021-03-25 | — | — | US | disclosed |
| CN-112423760-A | Ion channel modulators | 普拉克西斯精密药物股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20200377507-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200377506-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200377499-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200179358-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2020-06-11 | — | — | US | disclosed |
| EP-3548033-A1 | COMPOUNDS AND THEIR METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| WO-2019035951-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2018098499-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098499-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030881-B2 | Ion channel modulators | SCN1A, SCN1B, SCN2A | AAK1 1569/4885ALPL 3875/4885LPL 3438/4885 |
| US-20210087197-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | AAK1 2082/4885ALPL 4471/4885LPL 2822/4885 |
| US-12145939-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators | SCN1A, SCN2A, SCN5A | AAK1 1464/4885ALPL 4203/4885LPL 4244/4885 |
| US-20200377506-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | AAK1 3892/4885ALPL 4099/4885LPL 2581/4885 |
| US-12344615-B2 | Substituted pyridines as ion channel modulators | SCN1A, CACNA1A, SCN5A | AAK1 1087/4885ALPL 4062/4885LPL 4125/4885 |
| US-20250145629-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | AAK1 2082/4885ALPL 4471/4885LPL 2822/4885 |
| US-20250163068-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | AAK1 3892/4885ALPL 4099/4885LPL 2581/4885 |
| US-20260116885-A1 | ION CHANNEL MODULATORS | SCN1B, SCN1A, CACNA1S | AAK1 2690/4885ALPL 4616/4885LPL 2524/4885 |
| US-20200377507-A1 | ION CHANNEL MODULATORS | SCN1A, SCN1B, SCN2A | AAK1 1519/4885ALPL 3703/4885LPL 3302/4885 |
| US-20250129066-A1 | ION CHANNEL MODULATORS | SCN1A, SCN1B, SCN2A | AAK1 1569/4885ALPL 3875/4885LPL 3438/4885 |
| US-20250376475-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | AAK1 2082/4885ALPL 4471/4885LPL 2822/4885 |
| US-20200179358-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN2A | AAK1 3505/4885ALPL 3872/4885LPL 2053/4885 |
| US-20200377499-A1 | ION CHANNEL MODULATORS | SCN1A, SCN1B, SCN2A | AAK1 1569/4885ALPL 3875/4885LPL 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.